Fate Therapeutics Inc (NASDAQ:FATE)’s traded shares stood at 2.15 million during the last session, with the company’s beta value hitting 1.74. At the close of trading, the stock’s price was $5.27, to imply a decrease of -2.04% or -$0.11 in intraday trading. The FATE share’s 52-week high remains $8.83, putting it -67.55% down since that peak but still an impressive 69.07% since price per share fell to its 52-week low of $1.63. The company has a valuation of $522.99M, with an average of 2.82 million shares over the past 3 months.

Fate Therapeutics Inc (NASDAQ:FATE) trade information

After registering a -2.04% downside in the last session, Fate Therapeutics Inc (FATE) has traded red over the past five days. The stock hit a weekly high of 6.37, dropping -2.04% in its intraday price action. The 5-day price performance for the stock is -15.95%, and -25.14% over 30 days. With these gigs, the year-to-date price performance is 40.91%.

Fate Therapeutics Inc (FATE) estimates and forecasts

Looking at statistics comparing Fate Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Fate Therapeutics Inc (FATE) shares are 197.74% up over the last 6 months, with its year-to-date growth rate lower than industry average at -18.29% against 12.80%.

FATE Dividends

Fate Therapeutics Inc has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Fate Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.